A Phase II Study of Cisplatin, 5-Fluorouracil, Leucovorin, and Etoposide in Advanced Non-Small-Cell Lung Cancer
| Autor: | D. Coeffic, Olivier Rixe, Bernard Maitre, A. Benhammouda, B. Orcel, David Khayat, Cecil O. Borel, Thierry Petit, Jean-Philippe Derenne |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Leucovorin Phases of clinical research Gastroenterology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Mucositis medicine Humans Lung cancer Survival rate Etoposide Aged Chemotherapy business.industry Middle Aged medicine.disease Surgery Survival Rate Regimen Oncology Fluorouracil Female Cisplatin business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 20:128-131 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199704000-00004 |
| Popis: | The aim of this study was to define the efficacy of a combination of cisplatin, 5-fluorouracil (5-FU), leucovorin, and etoposide (VP-16) in locally advanced or metastatic non-small-cell lung cancer (NSCLC). From September 1991 to November 1994, 28 patients were treated with cisplatin, 100 mg/m2 i.v. on day 1; 5-FU and leucovorin, 500 mg/m2 on days 1, 2, 3, and 4 by i.v. continuous infusion; and VP-16, 70 mg/m2 i.v. on days 1, 2, 3, and 4 (combination, PFL-VP-16). Cycles were repeated every 3 weeks. There were 22 men and six women. The median age was 58 (range, 41-76). All had measurable diseases (one was stage IIIA, six were IIIB, and 21 were IV). None had previously received chemotherapy for metastatic disease. There was one complete response and six partial responses, for an overall response rate of 25% (95% confidence interval 9-41%). The median response duration and the overall survival were 8 and 9 months, respectively. Limiting toxicity was myelosuppression and oral mucositis. Grade 3 or 4 leucopenia was observed in 20% of all of the 95 cycles administered, and oral mucositis in 13%. No grade 3 or 4 renal toxicity occurred, and neurologic toxicities were limited (3% of the 28 patients experienced grade 3). PFL-VP-16 is active and can easily be administered to patients with advanced NSCLC. However, according to the results obtained with this schedule, VP-16 does not increase either response rate or survival compared with the regimen previously described by Vokes et al. (PFL). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|